Oyster Point Pharma Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize OC-01 and OC-02 in Greater ChinaGlobeNewsWire • 08/05/21
Oyster Point Pharma to Report Second Quarter 2021 Financial Results on August 5, 2021GlobeNewsWire • 08/04/21
Oyster Point Pharma Announces New Chairperson Appointment to Board of DirectorsGlobeNewsWire • 08/02/21
Oyster Point Pharma Announces Preclinical Data Highlighting Potent Activity of OC-01 (varenicline) and OC-02 (simpinicline) Against SARS-CoV-2 Virus and VariantsGlobeNewsWire • 07/01/21
Oyster Point Pharma Provides Key Supply Chain Insight For OC-01 (varenicline) Nasal SprayGlobeNewsWire • 06/29/21
Oyster Point Pharma to Participate in the LifeSci Partners Genetic Medicines SummitGlobeNewsWire • 06/21/21
Oyster Point Pharma Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial of OC-01 (varenicline) Nasal Spray for Patients with Neurotrophic KeratopathyGlobeNewsWire • 06/21/21
Adaptive Phage Therapeutics Announces Collaboration with Oyster Point Pharma to Target Ophthalmic DiseasesBusiness Wire • 06/10/21
Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics (APT) to Target Ophthalmic DiseasesGlobeNewsWire • 06/10/21
Oyster Point Introduces ETF Gene Therapy, First Candidate to Target Neurotrophic KeratopathyBenzinga • 06/03/21
Oyster Point Pharma Announces Preclinical Study Results and Pipeline Expansion with Enriched Tear Film (ETF™) Gene Therapy to Target Ocular Surface DiseasesGlobeNewsWire • 06/03/21
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/09/21
Oyster Point Pharma Reports First Quarter 2021 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/06/21
Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual MeetingGlobeNewsWire • 05/01/21
Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye DiseaseGlobeNewsWire • 03/02/21
Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare ConferenceGlobeNewsWire • 02/25/21
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/19/21
Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business HighlightsGlobeNewsWire • 02/18/21
Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021GlobeNewsWire • 02/12/21
Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/29/20
Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye DiseaseGlobeNewsWire • 12/18/20
Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific OfficersGlobeNewsWire • 12/07/20
Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)GlobeNewsWire • 12/01/20
Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare ConferenceGlobeNewsWire • 11/25/20